Fig. 9
From: Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
Increased survival in a nude mouse metastasis model of human breast cancer after treatment with TfRscFv-LipA2-p53 in combination with docetaxel. Beginning 10 days after tumor cell injection, twice weekly doses of TfRscFv-LipA2-p53 (20 µg p53 DNA/0.3 ml) with or without docetaxel (7.5 mg/Kg) were intravenously administered (5 animals per group). A total of 10 injections were administered. (a) shows the animal survival curves of the nude mice after various treatments and (b) shows the result of a repeat experiment focusing on comparison of the two targeting ligands, TfRscFv and Tf. The systemic administration of TfRscFv-LipA2-p53 via tail vein in combination with docetaxel significantly extended the life-span of the animals. Long term survivors were observed in the animals receiving the combination of TfRscFv-LipA2-p53 and docetaxel, with 60% in the first study (A) and 80% in the second study (B), while no long term survivors were observed in animals receiving either treatment alone.